Misplaced Pages

Aranidipine

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name O5-methyl O3-(2-oxopropyl)
CAS Number	86780-90-7
PubChem CID	2225
ChemSpider	2139
UNII	4Y7UR6X2PO
KEGG	D01562
ChEMBL	ChEMBL2104030
CompTox Dashboard (EPA)	DTXSID9048649
Chemical and physical data
Formula	C19H20N2O7
Molar mass	388.376 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2(=O))C(=O)OC
InChI InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3 Key:NCUCGYYHUFIYNU-UHFFFAOYSA-N
(verify)

Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.

References

1. "Aranidipine". PubMed. Retrieved 23 December 2018.
2. Gelatsis P (1997). "To Market, to Market – 1996". In Bristol JA, Robertson DW, Doherty AM, Hagmann WK, Plattner JJ, Wong WW, Trainor GL (eds.). Annual Reports in Medicinal Chemistry. San Diego: Academic Press. p. 306. ISBN 978-0-08-058376-1.

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Calcium channel blockers
• Dihydropyridines
• Carboxylate esters
• Ketones
• 2-Nitrophenyl compounds
• Methyl esters
• Cardiovascular system drug stubs